ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
| Image |  |
|---|---|
| Description | scientific article published on 25 July 2017 |
| Author/s |
author: Silvia Veganzones Alicia Valverde-Megías Julian Garcia Feijoo |
| Publication date | July 25, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |